Cargando…

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer

Metronomic chemotherapy has shown promising activity in numerous preclinical studies and also some phase II clinical studies involving various tumor types, and is currently undergoing phase III trial evaluation. Triple-negative breast cancer (TNBC) is an aggressive histological subtype with limited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Desidero, Teresa, Xu, Ping, Man, Shan, Bocci, Guido, Kerbel, Robert S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767441/ https://www.ncbi.nlm.nih.gov/pubmed/26623560

Ejemplares similares

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models
por: Hackl, Christina, et al.
Publicado: (2013)

Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth
por: Parra, Karla, et al.
Publicado: (2017)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial
por: Manji, Arif, et al.
Publicado: (2022)

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
por: Cazzaniga, M. E., et al.
Publicado: (2017)

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models()
por: Zhang, Libo, et al.
Publicado: (2017)

Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key
por: Rabanal, Connie, et al.
Publicado: (2017)

Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer
por: BALL, DOUGLAS W., et al.
Publicado: (2015)

Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies
por: Banchi, Marta, et al.
Publicado: (2022)

Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer
por: Reguera-Nuñez, Elaine, et al.
Publicado: (2019)

Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
por: Schito, Luana, et al.
Publicado: (2020)

Na(+)/H(+) exchanger NHE1 regulation modulates metastatic potential and epithelial-mesenchymal transition of triple-negative breast cancer cells
por: Amith, Schammim Ray, et al.
Publicado: (2016)

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
por: Allegrini, Giacomo, et al.
Publicado: (2012)

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
por: Allegrini, G, et al.
Publicado: (2008)

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
por: Kerklaan, B Milojkovic, et al.
Publicado: (2015)

An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids
por: Jyoti, Amar, et al.
Publicado: (2015)

RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models
por: Wong, Oi Kwan, et al.
Publicado: (2018)

Cripto-1 as a novel therapeutic target for triple negative breast cancer
por: Castro, Nadia P., et al.
Publicado: (2014)

Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer
por: Mitra Ghosh, Taraswi, et al.
Publicado: (2021)

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan
por: Bouche, Gauthier, et al.
Publicado: (2014)

ERβ inhibits cyclin dependent kinases 1 and 7 in triple negative breast cancer
por: Reese, Jordan M., et al.
Publicado: (2017)

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
por: Taschner-Mandl, Sabine, et al.
Publicado: (2015)

Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial–mesenchymal Transition in Aggressive Variant Prostate Cancers
por: Mitra Ghosh, Taraswi, et al.
Publicado: (2023)

Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
por: Khan, Kabir A., et al.
Publicado: (2020)

Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers
por: Kozin, Sergey V., et al.
Publicado: (2017)

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
por: Cazzaniga, M. E., et al.
Publicado: (2021)

Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents
por: Sestak, Vit, et al.
Publicado: (2015)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells
por: Hasegawa, Masanori, et al.
Publicado: (2016)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer
por: Iskit, Sedef, et al.
Publicado: (2016)

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
por: Cazzaniga, Marina Elena, et al.
Publicado: (2022)

microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers
por: Gasparini, Pierluigi, et al.
Publicado: (2014)

Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models
por: Mainetti, Leandro E., et al.
Publicado: (2020)

Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer
por: Bansal, Nidhi, et al.
Publicado: (2015)

Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2015)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Whether low-dose metronomic oral cyclophosphamide improves the response to docetaxel in first-line treatment of non-triple-negative metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tn46glmcf3r9rjq5uniatpin79